在美国林业发展局的核准和主要疾病的扩大使用推动下,全球生物类似市场将从2024年的22.6B增加到2033年的171.8B。 The global biosimilars market is set to surge from $22.6B in 2024 to $171.8B by 2033, driven by U.S. FDA approvals and expanded use in key diseases.

预计全球生物类同市场将从2024年的225.8亿美元增长到2033年的171.79亿美元,美国林业发展局核准超过70亿美元,并扩大了肿瘤、糖尿病和自免疫疾病的使用范围。 The global biosimilars market is expected to grow from $22.58 billion in 2024 to $171.79 billion by 2033, fueled by U.S. FDA approvals exceeding 70 and expanding use in oncology, diabetes, and autoimmune diseases. 新的2024-2025年批准包括治疗哮喘、过敏、自发性免疫疾病和眼病。 New 2024–2025 approvals include treatments for asthma, allergies, autoimmune conditions, and eye disease. 北美领先,而亚太区域增长最快,因为当地制造业增加。 North America leads, while Asia-Pacific grows fastest due to increased local manufacturing. 尽管存在生产成本和免疫能力等挑战,但监管支持和创新正在推动患者获得服务,并在全世界节省费用。 Despite challenges like production costs and immunogenicity, regulatory support and innovation are boosting patient access and cost savings worldwide.